Recent advances in ocular drug delivery

Drug Development and Industrial Pharmacy

Volumn 39, Issue 11, 2013, Pages 1599-1617

  Achouri, Djamila ^a,b,c   Alhanout, Kamel ^c,d   Piccerelle, Philippe ^a,c   Andrieu, Véronique ^c  

^a AVIGNON UNIVERSITÉ   (France)

^b Thèse CIFRE Horus Pharma ^*  (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Al Andalus University   (Syrian Arab Republic)

Author keywords

Bioavailability; Drug delivery systems; in situ gelling system; Particulate systems

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BENZALKONIUM CHLORIDE; BETA CYCLODEXTRIN; BETAXOLOL; CARBOMER; CARBOPOL 1342NF; CARBOPOL 940; CARBOPOL 974P; CHLORAMPHENICOL; CIPROFLOXACIN; CITRATE SODIUM; CLOROCIL; CUBOSOME; CYCLODEXTRIN; CYCLOSPORIN A; DECANOIC ACID; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DICLOFENAC; DRUG CARRIER; EDETIC ACID; EUDRAGIT; EXCIPIENT; FUSIDIC ACID; GAMMA CYCLODEXTRIN; GEL LARMES; GELLAN; HYDROXYPROPYLMETHYLCELLULOSE; INDOMETACIN; KELCOGEL; KELTON; LATANOPROST; LINEZOLID; LIPOSOME; METHOCEL E50LV; METHOCEL F4M; NANOPARTICLE; NIOSOME; PHOSPHATIDYLCHOLINE; POLIDOCANOL; POLOXAMER; POLYMER; POLYSORBATE 60; POLYSORBATE 80; POVIDONE; PRODRUG; TAUROCHOLIC ACID; TIMOPTOL XE; UNCLASSIFIED DRUG; UNIL 088; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANATOMY; COLLOID; CORNEA EPITHELIUM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; GEL; GELATION; HUMAN; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; LACRIMATION; MICROEMULSION; NANOEMULSION; NONHUMAN; OSMOSIS; PATIENT COMPLIANCE; PH; REVIEW; SUSTAINED DRUG RELEASE; TEMPERATURE DEPENDENCE; VISCOSITY;

ADHESIVENESS; ADMINISTRATION, OPHTHALMIC; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; EYE; EYE DISEASES; HUMANS; OCULAR PHYSIOLOGICAL PHENOMENA; PHYSICOCHEMICAL PHENOMENA; PRESCRIPTION DRUGS; PRODRUGS; SOLUBILITY; VISCOSITY;

EID: 84885610489     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.736515     Document Type: Review

References (93)

1. Stjernschantz J, Astin M. (1993). Anatomy and physiology of the eye, physiological aspects of ocular drug therapy. In: Edman P, editor. Biopharmaceutics in Ocular Drug Delivery. Boca Raton: CRC Press, 1-25
2. Robinson JC. (2003). Ocular anatomy and physiology relevant to ocular drug delivery. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York: Etats-Unis, 29-57
3. Shell JW. (1982). Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol, 26:207-218
4. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. (2004). Cationic vectors in ocular drug delivery. J Drug Target, 12:623-633
5. Janoria KG, Hariharan S, Dasari CR, Mitra AK. (2007). Recent patents and advances in ophthalmic drug delivery. Recent Pat Drug Deliv Formul, 1:161-170
6. Sirbat D, Marchal-Heussler L, Hoffman M, Maincent P (2000). [Ways to improve ocular bioavailability for topical applications]. J Fr Ophtalmol, 23:505-9; quiz 523
7. Kompella UB, Kadam RS, Lee VH. (2010). Recent advances in ophthalmic drug delivery. Ther Deliv, 1:435-456
8. Lallemand F, Perottet P, Felt-Baeyens O, Kloeti W, Philippoz F, Marfurt J et al. (2005). A water-soluble prodrug of cyclosporine A for ocular application: A stability study. Eur J Pharm Sci, 26:124-129
9. Tirucherai GS, Dias C, Mitra AK. (2002). Corneal permeation of ganciclovir: Mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther, 18:535-548
10. Kaur IP, Kanwar M. (2002). Ocular preparations: The formulation approach. Drug Dev Ind Pharm, 28:473-493
11. Kaur IP, Chhabra S, Aggarwal D. (2004). Role of cyclodextrins in ophthalmics. Curr Drug Deliv, 1:351-360
12. Loftsson T, Stefánsson E. (2002). Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand, 80:144-150
13. Saari KM, Nelimarkka L, Ahola V, Loftsson T, Stefánsson E.(2006). Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol, 244:620-626
14. Sigurdsson HH, Konráethsdósttir F, Loftsson T, Stefánsson E. (2007). Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand, 85:598-602
15. Singh SK, Bandyopadhyay P, Hassan S, inventors. (2004). Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride. US patent 0019012
16. Loftsson T, Stefansson E, inventors. (2007). Cyclodextrin nanotechnology for ophthalmic drug delivery. US patent 0020336
17. Ito Y, Nagai N, Shimomura Y. (2010). Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-ß-cyclodextrin in rabbit. Biol Pharm Bull, 33:1574-1578
18. Sasaki H, Igarashi Y, Nagano T, Nishida K, Nakamura J. (1995). Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic β-blockers. Pharm Res, 12:1146-1150
19. Nanjawade BK, Manvi FV, Manjappa AS. (2007). In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release, 122:119-134
20. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. (1998). Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res, 17:33-58
21. Ludwig A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev, 57:1595-1639
22. Laroche L, Arrata M, Brasseur G, Lagoutte F, Le Mer Y, Lumbroso P et al (1991). [Treatment of dry eye syndrome with lacrimal gel: A randomized multicenter study]. J Fr Ophtalmol, 14:321-326
23. Johnson ME, Murphy PJ, Boulton M. (2006). Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol, 244:109-112
24. Khamar BM, inventor. (2001). Ophthalmic formulation comprising a β blocker and carbopol. EP patent 1137407
25. Lu GW. (2010). Recent advances in developing ophthalmic formulations: A patent review. Recent Pat Drug Deliv Formul, 4:49-57
26. Gurtler F, Gurny R. (1995). Patent literature review of ophthalmic inserts. Drug Dev Ind Pharm, 21:1-18
27. Escobar-Chávez JJ, López-Cervantes M, Naül A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. (2006). Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharm Sci, 9:339-358
28. El-Kamel AH. (2002). In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm, 241:47-55
29. Shastri D, Patel L, Parikh R. (2010). Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. J Young Pharm, 2:116-120
30. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. (2001). In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm, 229:29-36
31. Johnson ME, Murphy PJ, Boulton M. (2008). Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci, 85:750-757
32. Vyas SP, Ramchandraiah S, Jain CP, Jain SK. (1992). Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery. J Microencapsul, 9:347-355
33. Maurice DM, Srinivas SP. (1992). Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: Comparison with scintigraphy. J Pharm Sci, 81:615-619
34. Carlfors J, Edsman K, Petersson R, Jörnving K. (1998). Rheological evaluation of Gelrite in situ gels for ophthalmic use. Eur J Pharm Sci, 6:113-119
35. Balasubramaniam J, Pandit JK. (2003). Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv, 10:185-191
36. El-Kamel A, Al-Dosari H, Al-Jenoobi F. (2006). Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv, 13:55-59
37. Sultana Y, Aqil M, Ali A, Zafar S. (2006). Evaluation of carbopolmethyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol, 11:313-319
38. Mohan EC. (2009). Preparation and evaluation of in-situ-gels for ocular drug delivery. J Pharm Res, 2:1089-1094
39. Séchoy O, TissiülG, Sébastian C, Maurin F, Driot JY, Trinquand C. (2000). A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm, 207:109-116
40. Demailly P, Allaire C, Trinquand C; Once-daily Carteolol Study Group (2001). Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol, 85:921-924
41. Trinquand C, Romanet JP, Nordmann JP, Allaire C; Groupe détude.(2003). [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. J Fr Ophtalmol, 26:131-136
42. Lang JC, Keister JC, Missel PJT, Stancioff DJ, inventors. (1995). Use of carrageenans in topical ophthalmic compositions. US patent 5403841
43. Srividya B, Cardoza RM, Amin PD. (2001). Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release, 73:205-211
44. Lin HR, Sung KC, inventors. (2003). Ophthalmic drug delivery formulations and method for preparing the same. US patent 6511660
45. Liu Z, Pan W, Nie S, Zhang L, Yang X, Li J. (2005). Preparation and evaluation of sustained ophthalmic gel of enoxacin. Drug Dev Ind Pharm, 31:969-975
46. Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. (2006). Study of an alginate/ HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm, 315:12-17
47. Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T.(2007). Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv, 14:507-515
48. Singh V, Bushetti SS, Appala R, Shareef A, Imam SS, Singh M.(2010). Stimuli-sensitive hydrogels: A novel ophthalmic drug delivery system. Indian J Ophthalmol, 58:477-481
49. Schoenwald RD. (1993). Pharmacokinetics in ocular drug delivery. In: Edman P, editor. Biopharmaceutics of Ocular Drug Delivery. Mitra AK, 159-193
50. Pietzyk B, Henschke K. (2000). Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions. Int J Pharm, 196:215-218
51. Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies. AAPS PharmSciTech, 8:1
52. Shen Y, Tu J. (2007). Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J, 9:E371-E377
53. Mehanna MM, Elmaradny HA, Samaha MW. (2009). Mucoadhesive liposomes as ocular delivery system: Physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm, 36:108-118
54. Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. (2010). Liposomes as an ocular delivery system of fluconazole: In-vitro studies. Acta Ophthalmol, 88:901-904
55. Budai L, HajdúlM, Budai M, Gróf P, Béni S, Noszál B et al. (2007). Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. Int J Pharm, 343:34-40
56. Hosny KM. (2009). Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. AAPS PharmSciTech, 10:1336-1342
57. Hosny KM. (2010). Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech, 11:241-246
58. Zhang J, Guan P, Wang T, Chang D, Jiang T, Wang S. (2009). Freezedried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. J Pharm Pharmacol, 61:1171-1178
59. Zhang J, Wang S. (2009). Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: Tolerance, precorneal retention and anti-cataract effect. Int J Pharm, 372:66-75
60. Aggarwal D, Kaur IP. (2005). Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm, 290:155-159
61. Kaur IP, Aggarwal D, Singh H, Kakkar S. (2010). Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch Clin Exp Ophthalmol, 248:1467-1472
62. Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm, 306:71-82
63. Aggarwal D, Pal D, Mitra AK, Kaur IP. (2007). Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm, 338:21-26
64. Abdelbary G, El-Gendy N. (2008). Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech, 9:740-747
65. Garg G, Saraf S, Saraf S. (2007). Cubosomes: An overview. Biol Pharm Bull, 30:350-353
66. Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X et al. (2010). Selfassembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm, 396:179-187
67. Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL et al. (2010). Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin, 31:990-998
68. Klang SH, Siganos CS, Benita S, Frucht-Pery J. (1999). Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn. J Control Release, 57:19-27
69. Abdulrazik M, Tamilvanan S, Khoury K, Benita S. (2001). Ocular delivery of cyclosporin A. II. Effect of submicron emulsions surface charge on ocular distribution of topical cyclosporin A. Paris: Editions De santül
70. Benita S, Lambert G, inventors. (2003). Method and composition for dry eye treatment. US patent 0108626
71. Bague S, Betty P, Sebastien GJ, inventors. (2006). Oil in water type emulsion with low concentration of cationic agent and positive zeta potentiel. US patent 0100288
72. Klang S, Abdulrazik M, Benita S. (2000). Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol, 5:521-532
73. Gan L, Gan Y, Zhu C, Zhang X, Zhu J. (2009). Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: In vitro and in vivo results. Int J Pharm, 365:143-149
74. Fialho SL, da Silva-Cunha A. (2004). New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol, 32:626-632
75. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. (2009). Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech, 10:808-819
76. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. (1991). [Nanocapsules of β-blocking agents: A new drug carrier in ophthalmology. Application to medical treatment of glaucoma in rabbits]. J Fr Ophtalmol, 14:371-375
77. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. (1993). Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res, 10:386-390
78. De Campos AM, Sánchez A, Alonso MJ. (2001). Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm, 224:159-168
79. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. (2002). Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 23:3247-3255
80. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G et al. (2003). Influence of preparation conditions on acyclovirloaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res, 20:584-590
81. De Campos AM, Diebold Y, Carvalho EL, Sánchez A, Alonso MJ.(2004). Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm Res, 21:803-810
82. Enriquez De Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, Vila A et al. (2006). Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci, 47:1416-1425
83. Vega E, Egea MA, Valls O, Espina M, García ML. (2006). Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci, 95:2393-2405
84. Kao HJ, Lin HR, Lo YL, Yu SP. (2006). Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol, 58:179-186
85. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm, 340:126-133
86. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. (2008). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm, 68:513-525
87. Yenice I, Mocan MC, Palaska E, Bochot A, Bilensoy E, Vural I et al. (2008). Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res, 87:162-167
88. Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H. (2011). Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci, 52:1516-1521
89. Ibrahim HK, El-Leithy IS, Makky AA. (2010). Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm, 7:576-585
90. Uner M, Yener G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2:289-300
91. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm, 238:241-245
92. Pierscionek BK, Li Y, Yasseen AA, Colhoun LM, Schachar RA, Chen W. (2010). Nanoceria have no genotoxic effect on human lens epithelial cells. Nanotechnology, 21:035102
93. Chen J, Patil S, Seal S, McGinnis JF. (2008). Nanoceria particles prevent ROI-induced blindness. Adv Exp Med Biol, 613:53-59